Cingulate Inc. (CING)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Shane J. Schaffer Pharm.D. | Co-Founder, CEO & Chairman of the Board | 570.78k | -- | 1975 |
| Ms. Jennifer L. Callahan CPA | Senior VP, CFO & Secretary | 358.98k | -- | 1971 |
| Dr. Laurie A. Myers M.B.A., Ph.D. | Executive VP & COO | 367.47k | -- | 1957 |
| Dr. Raul R. Silva M.D. | Co-Founder, Executive VP & Chief Science Officer | -- | -- | 1958 |
| Dr. Matthew N. Brams M.D. | Co-Founder, Executive VP & Chief Medical Officer | 244.79k | -- | 1964 |
| Thomas Dalton | Vice President of Investor & Public Relations | -- | -- | -- |
Cingulate Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 13
Description
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD; CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical trials for the treatment of ADHD in children; and CTx-2103 (buspirone) for the treatment of anxiety. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available